LM11A-31 explained

LM11A-31 is an experimental drug developed for Alzheimer's disease and Huntington's disease.^{[1] [2] [3] [4] [5] [6] [7] [8]}

Notes and References

1. Simmons . Danielle A. . Knowles . Juliet K. . Belichenko . Nadia P. . Banerjee . Gargi . Finkle . Carly . Massa . Stephen M. . Longo . Frank M. . A Small Molecule p75NTR Ligand, LM11A-31, Reverses Cholinergic Neurite Dystrophy in Alzheimer's Disease Mouse Models with Mid- to Late-Stage Disease Progression . PLoS ONE . 9 . 8 . 2014-08-25 . 1932-6203 . 10.1371/journal.pone.0102136 . free . e102136. 4143160 .
2. Elshaer . Sally L. . Alwhaibi . Abdulrahman . Mohamed . Riyaz . Lemtalsi . Tahira . Coucha . Maha . Longo . Frank M. . El-Remessy . Azza B. . Modulation of the p75 neurotrophin receptor using LM11A-31 prevents diabetes-induced retinal vascular permeability in mice via inhibition of inflammation and the RhoA kinase pathway . Diabetologia . 62 . 8 . 2019 . 0012-186X . 31073629 . 8808141 . 10.1007/s00125-019-4885-2 . 1488–1500.
3. Simmons . Danielle A. . Mills . Brian D. . Butler III . Robert R. . Kuan . Jason . McHugh . Tyne L.M. . Akers . Carolyn . Zhou . James . Syriani . Wassim . Grouban . Maged . Zeineh . Michael . Longo . Frank M. . Neuroimaging, Urinary, and Plasma Biomarkers of Treatment Response in Huntington's Disease: Preclinical Evidence with the p75NTR Ligand LM11A-31 . Neurotherapeutics . Elsevier BV . 18 . 2 . 2021 . 1878-7479 . 10.1007/s13311-021-01023-8 . 1039–1063. 8423954 .
4. Nasoohi . Sanaz . Tayefeh Ghahremani . Pargol . Alehossein . Parsa . Elyasizadeh . Siyamak . BaniArdalan . Soha . Ismael . Saifudeen . Vatanpour . Hossein . Ahmadiani . Abolhassan . Ishrat . Tauheed . The p75 neurotrophin receptor inhibitor, LM11A-31, ameliorates acute stroke injury and modulates astrocytic proNGF . Experimental Neurology . Elsevier BV . 359 . 2023 . 0014-4886 . 10.1016/j.expneurol.2022.114161 . 114161.
5. Simmons . Danielle A . James . Michelle L . Belichenko . Nadia P . Semaan . Sarah . Condon . Christina . Kuan . Jason . Shuhendler . Adam J . Miao . Zheng . Chin . Frederick T . Longo . Frank M . TSPO–PET imaging using [18F]PBR06 is a potential translatable biomarker for treatment response in Huntington’s disease: preclinical evidence with the p75NTR ligand LM11A-31 . Human Molecular Genetics . 27 . 16 . 2018-08-15 . 0964-6906 . 29860333 . 6077813 . 10.1093/hmg/ddy202 . 2893–2912.
6. Nguyen . Thuy-Vi V. . Crumpacker . Rachel H. . Calderon . Kylie E. . Garcia . Frankie G. . Zbesko . Jacob C. . Frye . Jennifer B. . Gonzalez . Selena . Becktel . Danielle A. . Yang . Tao . Tavera-Garcia . Marco A. . Morrison . Helena W. . Schnellmann . Rick G. . Longo . Frank M. . Doyle . Kristian P. . Post-Stroke Administration of the p75 Neurotrophin Receptor Modulator, LM11A-31, Attenuates Chronic Changes in Brain Metabolism, Increases Neurotransmitter Levels, and Improves Recovery . Journal of Pharmacology and Experimental Therapeutics . American Society for Pharmacology & Experimental Therapeutics (ASPET) . 380 . 2 . 2021-12-10 . 0022-3565 . 10.1124/jpet.121.000711 . 126–141. 11048261 .
7. Yin . Guo Nan . Ock . Jiyeon . Limanjaya . Anita . Minh . Nguyen Naht . Hong . Soon-Sun . Yang . Tao . Longo . Frank M. . Ryu . Ji-Kan . Suh . Jun-Kyu . Oral Administration of the p75 Neurotrophin Receptor Modulator, LM11A-31, Improves Erectile Function in a Mouse Model of Cavernous Nerve Injury . The Journal of Sexual Medicine . 18 . 1 . 2021 . 10.1016/j.jsxm.2020.10.015 . 17–28. free .
8. Shanks . Hayley R. C. . Börjesson‐Hanson . Anne . Windisch . Manfred . Massa . Stephen M. . Longo . Frank M. . Schmitz . Taylor W. . Age‐dependent effects of the p75 neurotrophin receptor modulator LM11A‐31 on Alzheimer’s disease biomarkers in a 26‐week safety and exploratory endpoint trial . Alzheimer's & Dementia . December 2022 . 18 . S10 . 10.1002/alz.069079.